No Data
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Yunkang Group Limited Faces Director Vacancy After Passing of INED
Yunkang Group Limited's (HKG:2325) Largest Shareholder, CEO Yong Zhang Sees Holdings Value Fall by 13% Following Recent Drop
Yunkang Group to Renew Its Lease, Related Services Agreement for Premises in Science City, Guangzhou
Yunkang Group Secures 2025 Property Leasing Deal
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
